These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Persister M. leprae after introductory rifampicin followed by dapsone therapy. Sreevatsa ; Girdhar BK; Desikan KV Lepr India; 1981 Jul; 53(3):350-3. PubMed ID: 7278139 [TBL] [Abstract][Full Text] [Related]
7. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone. Gelber RH; Humphres RC; Fieldsteel AH Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770 [TBL] [Abstract][Full Text] [Related]
9. [Effect of L-tetramisol associated with rifampicin in patients with lepromatous leprosy. L-tetramisol in patients with lepromatous leprosy]. Galmarini M; Riera CM; Ripoll J; Orozco MA; Katz J Med Cutan Ibero Lat Am; 1978; 6(3-4):179-83. PubMed ID: 398916 [TBL] [Abstract][Full Text] [Related]
10. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. Dhople AM; Ibanez MA Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013 [TBL] [Abstract][Full Text] [Related]
11. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy. Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603 [TBL] [Abstract][Full Text] [Related]
12. [2 cases of recurrence resistant to rifampicin in lepromatous leprosy]. Cottenot F; Wallach D; Flageul B; Pennec J; Wastiaux K Ann Dermatol Venereol; 1983; 110(9):703-4. PubMed ID: 6660769 [No Abstract] [Full Text] [Related]
13. [Study on short-term clinical trial of R-77-3 [3-(4-cyclo-pentyl-l-piperazinyl) imino methyl rifamycin SV] by mouse foot-pad technique]. Wang HY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Oct; 10(5):374-5. PubMed ID: 2978259 [No Abstract] [Full Text] [Related]
15. Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy. Ghosh S; McDougall AC; Hazra SK; Yawalkar SJ Indian J Dermatol; 1981 Oct; 26(4):1-6. PubMed ID: 6754585 [No Abstract] [Full Text] [Related]
16. Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. Indian J Lepr; 1997; 69(2):121-9. PubMed ID: 9290963 [TBL] [Abstract][Full Text] [Related]
17. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy. Chandorkar AG; Burte NP; Gade RK; Bulakh PM Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381 [TBL] [Abstract][Full Text] [Related]
18. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy. Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592 [TBL] [Abstract][Full Text] [Related]
19. Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Kar HK; Roy RG Indian J Lepr; 1984; 56(4):835-9. PubMed ID: 6549453 [TBL] [Abstract][Full Text] [Related]
20. Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report. Katoch K; Sreevatsa ; Ramanathan U; Ramu G Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):1-9. PubMed ID: 2453596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]